CardioDx
13
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.7%
1 terminated/withdrawn out of 13 trials
92.3%
+5.8% vs industry average
0%
0 trials in Phase 3/4
8%
1 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Role: lead
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
Role: lead
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
Role: lead
Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
Role: lead
Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease
Role: lead
Understanding the Effect of Metformin on Corus CAD (or ASGES)
Role: lead
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
Role: lead
PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis
Role: lead
A Registry to Evaluate Patterns of Care Associated With the Use of Corus CAD (or ASGES) in Primary Care Settings
Role: lead
Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.
Role: lead
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
Role: lead
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Role: lead
Diagnostic Investigation of Sudden Cardiac Event Risk
Role: lead
All 13 trials loaded